In case you missed it, on June 3, 2016, Knoxville-based Provision Healthcare announced a new joint venture (JV) between its subsidiary, Provision Asia, and Shenzhen Hairong International Medical Development Co., Ltd., a subsidiary of Shenzhen Neptunus Bioengineering Co. The JV is called Provision China. As part of the deal, Hairong International will also invest US $25 million in Provision Healthcare.
According to the Provision Healthcare press release about the deal:
“Provision China will develop cancer centers and proton therapy centers in China, provide consultation and support services for the design, construction, development and operation of proton therapy centers and cancer treatment centers in China (including physician and staff training, operations management support, and clinical research), distribute Proton Therapy Systems in China that are manufactured by Provision Healthcare, LLC and its affiliates, and provide service and maintenance for proton therapy systems.”
For more details on the deal, visit the Provision Healthcare press release.